SARS-CoV-2 Infection and Lung Regeneration

Overview

Journal Clin Microbiol Rev

Publisher American Society for Microbiology

Specialty Microbiology

Date 2022 Feb 2

PMID 35107300

Authors

Fuxiaonan Zhao

Qingwen Ma

Qing Yue

Huaiyong Chen

Affiliations

Soon will be listed here.

Abstract

The lung is the primary site of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced immunopathology whereby the virus enters the host cells by binding to angiotensin-converting enzyme 2 (ACE2). Sophisticated regeneration and repair programs exist in the lungs to replenish injured cell populations. However, known resident stem/progenitor cells have been demonstrated to express ACE2, raising a substantial concern regarding the long-term consequences of impaired lung regeneration after SARS-CoV-2 infection. Moreover, clinical treatments may also affect lung repair from antiviral drug candidates to mechanical ventilation. In this review, we highlight how SARS-CoV-2 disrupts a program that governs lung homeostasis. We also summarize the current efforts of targeted therapy and supportive treatments for COVID-19 patients. In addition, we discuss the pros and cons of cell therapy with mesenchymal stem cells or resident lung epithelial stem/progenitor cells in preventing post-acute sequelae of COVID-19. We propose that, in addition to symptomatic treatments being developed and applied in the clinic, targeting lung regeneration is also essential to restore lung homeostasis in COVID-19 patients.

Citing Articles

Respiratory long COVID in aged hamsters features impaired lung function post-exercise with bronchiolization and fibrosis.

Heydemann L, Ciurkiewicz M, Stork T, Zdora I, Hulskotter K, Gregor K Nat Commun. 2025; 16(1):2080.

PMID: 40021627 PMC: 11871369. DOI: 10.1038/s41467-025-57267-x.

Establishment of a bat lung organoid culture model for studying bat-derived infectious diseases.

Elbadawy M, Saito N, Kato Y, Hayashi K, Abugomaa A, Kobayashi M Sci Rep. 2025; 15(1):4035.

PMID: 39900611 PMC: 11791068. DOI: 10.1038/s41598-025-88621-0.

Tracking inflammation resolution signatures in lungs after SARS-CoV-2 omicron BA.1 infection of K18-hACE2 mice.

Carolin A, Yan K, Bishop C, Tang B, Nguyen W, Rawle D PLoS One. 2024; 19(11):e0302344.

PMID: 39531435 PMC: 11556745. DOI: 10.1371/journal.pone.0302344.

Inhibition of SARS-CoV-2 growth in the lungs of mice by a peptide-conjugated morpholino oligomer targeting viral RNA.

Sakai A, Singh G, Khoshbakht M, Bittner S, Lohr C, Diaz-Tapia R Mol Ther Nucleic Acids. 2024; 35(4):102331.

PMID: 39376996 PMC: 11456799. DOI: 10.1016/j.omtn.2024.102331.

Comparative SARS-CoV-2 Omicron BA.5 variant and D614G-Wuhan strain infections in ferrets: insights into attenuation and disease progression during subclinical to mild COVID-19.

Barroso-Arevalo S, Sanchez-Morales L, Porras N, Diaz-Frutos M, Barasona J, Isla J Front Vet Sci. 2024; 11:1435464.

PMID: 39211479 PMC: 11358085. DOI: 10.3389/fvets.2024.1435464.

References

Kumar A, Cao W, Endrias K, Kuchipudi S, Mittal S, Sambhara S . Innate lymphoid cells (ILC) in SARS-CoV-2 infection. Mol Aspects Med. 2021; 80:101008. PMC: 8361007. DOI: 10.1016/j.mam.2021.101008. View

Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X . Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment. Engineering (Beijing). 2020; 6(10):1153-1161. PMC: 7102606. DOI: 10.1016/j.eng.2020.02.006. View

Zeiss C, Compton S, Veenhuis R . Animal Models of COVID-19. I. Comparative Virology and Disease Pathogenesis. ILAR J. 2021; 62(1-2):35-47. PMC: 8083356. DOI: 10.1093/ilar/ilab007. View

Kawasuji H, Morinaga Y, Tani H, Kimura M, Yamada H, Yoshida Y . Delayed neutralizing antibody response in the acute phase correlates with severe progression of COVID-19. Sci Rep. 2021; 11(1):16535. PMC: 8368204. DOI: 10.1038/s41598-021-96143-8. View

Ding B, Nolan D, Guo P, Babazadeh A, Cao Z, Rosenwaks Z . Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization. Cell. 2011; 147(3):539-53. PMC: 3228268. DOI: 10.1016/j.cell.2011.10.003. View

Xu X, Jiang W, Chen L, Xu Z, Zhang Q, Zhu M . Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. Clin Transl Med. 2021; 11(2):e297. PMC: 7839959. DOI: 10.1002/ctm2.297. View

McConnell A, Yao C, Yeckes A, Wang Y, Selvaggio A, Tang J . p53 Regulates Progenitor Cell Quiescence and Differentiation in the Airway. Cell Rep. 2016; 17(9):2173-2182. DOI: 10.1016/j.celrep.2016.11.007. View

Rawlins E, Okubo T, Xue Y, Brass D, Auten R, Hasegawa H . The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar, epithelium. Cell Stem Cell. 2009; 4(6):525-34. PMC: 2730729. DOI: 10.1016/j.stem.2009.04.002. View

Zhang H, Rostami M, Leopold P, Mezey J, OBeirne S, Strulovici-Barel Y . Expression of the SARS-CoV-2 Receptor in the Human Airway Epithelium. Am J Respir Crit Care Med. 2020; 202(2):219-229. PMC: 7365377. DOI: 10.1164/rccm.202003-0541OC. View

10.

Gad E, Salama A, El-Shafie M, Arafa H, Abdelsalam R, Khattab M . The Anti-fibrotic and Anti-inflammatory Potential of Bone Marrow-Derived Mesenchymal Stem Cells and Nintedanib in Bleomycin-Induced Lung Fibrosis in Rats. Inflammation. 2019; 43(1):123-134. DOI: 10.1007/s10753-019-01101-2. View

11.

Brechbuhl H, Ghosh M, Smith M, Smith R, Li B, Hicks D . β-catenin dosage is a critical determinant of tracheal basal cell fate determination. Am J Pathol. 2011; 179(1):367-79. PMC: 3123883. DOI: 10.1016/j.ajpath.2011.03.016. View

12.

Cicco S, Cicco G, Racanelli V, Vacca A . Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment. Mediators Inflamm. 2020; 2020:7527953. PMC: 7366221. DOI: 10.1155/2020/7527953. View

13.

Liu Q, Liu K, Cui G, Huang X, Yao S, Guo W . Lung regeneration by multipotent stem cells residing at the bronchioalveolar-duct junction. Nat Genet. 2019; 51(4):728-738. DOI: 10.1038/s41588-019-0346-6. View

14.

Lee T . Host tissue response in stem cell therapy. World J Stem Cells. 2010; 2(4):61-6. PMC: 2964154. DOI: 10.4252/wjsc.v2.i4.61. View

15.

Khatri M, Richardson L, Meulia T . Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model. Stem Cell Res Ther. 2018; 9(1):17. PMC: 5789598. DOI: 10.1186/s13287-018-0774-8. View

16.

Cerrada A, De La Torre P, Grande J, Haller T, Flores A, Perez-Gil J . Human decidua-derived mesenchymal stem cells differentiate into functional alveolar type II-like cells that synthesize and secrete pulmonary surfactant complexes. PLoS One. 2014; 9(10):e110195. PMC: 4198213. DOI: 10.1371/journal.pone.0110195. View

17.

Silva J, Lopes-Pacheco M, Paz A, Cruz F, Melo E, de Oliveira M . Mesenchymal Stem Cells From Bone Marrow, Adipose Tissue, and Lung Tissue Differentially Mitigate Lung and Distal Organ Damage in Experimental Acute Respiratory Distress Syndrome. Crit Care Med. 2017; 46(2):e132-e140. DOI: 10.1097/CCM.0000000000002833. View

18.

Lukomska B, Stanaszek L, Zuba-Surma E, Legosz P, Sarzynska S, Drela K . Challenges and Controversies in Human Mesenchymal Stem Cell Therapy. Stem Cells Int. 2019; 2019:9628536. PMC: 6481040. DOI: 10.1155/2019/9628536. View

19.

Chen H, Matsumoto K, Brockway B, Rackley C, Liang J, Lee J . Airway epithelial progenitors are region specific and show differential responses to bleomycin-induced lung injury. Stem Cells. 2012; 30(9):1948-60. PMC: 4083019. DOI: 10.1002/stem.1150. View

20.

Giangreco A, Reynolds S, Stripp B . Terminal bronchioles harbor a unique airway stem cell population that localizes to the bronchoalveolar duct junction. Am J Pathol. 2002; 161(1):173-82. PMC: 1850682. DOI: 10.1016/S0002-9440(10)64169-7. View